群体药代动力学/药效学研究提示,对合并早期肺炎和肾脏清除增强的机械通气重症患者,头孢洛林每日剂量可持续输注
研究纳入18例肌酐清除率83–309 mL/min的重症患者,建立头孢洛林群体药代动力学模型并行蒙特卡洛模拟。头孢洛林清除率随肌酐清除率非线性升高;现行600 mg每12小时方案对肺炎链球菌有效,对MRSA无效。作者认为负荷600 mg后以50 mg/h持续输注对MRSA可能更合适。
要点
- 头孢洛林清除率随肌酐清除率升高呈非线性增加,浓度和达标概率随之下降。
- 现行600 mg每12小时方案对肺炎链球菌CFR>86%,对MRSA的CFR为21%–67%。
- 负荷600 mg后50 mg/h持续输注可能更适合MRSA感染。
核心结论
- 作者认为,现行头孢洛林推荐剂量似乎足以覆盖合并肾脏清除增强的ICU患者中的肺炎链球菌,但不能覆盖MRSA。
- 在受试方案中,负荷600 mg后以50 mg/h持续输注对MRSA感染可能更合适。
研究设计与样本
- 采用18例患者的药代动力学数据建立群体药代动力学模型,患者肌酐清除率83–309 mL/min。
- 通过蒙特卡洛模拟计算五种给药方案对肺炎链球菌和MRSA的PTA与CFR;研究注册于ClinicalTrials.gov(NCT03025841)。
主要发现
- 头孢洛林清除率随肌酐清除率升高呈非线性增加,肌酐清除率升高时浓度更低、达到药代动力学/药效学靶值的概率更低。
- 现行推荐方案下,MIC低于0.125 mg/L时,整个给药间隔内游离头孢洛林浓度高于MIC的概率大于90%。
- 考虑MIC分布,现行方案对MRSA感染无效(CFR为21%–67%,随肌酐清除率而异),但对肺炎链球菌感染有效(CFR>86%)。
关键数值与推荐
- 现行推荐剂量为600 mg每12小时一次。
- MIC低于0.125 mg/L时,现行方案整个给药间隔内游离药物浓度高于MIC的概率大于90%。
- 现行方案对MRSA的CFR为21%–67%(随肌酐清除率而异),对肺炎链球菌的CFR>86%。
临床怎么用
- 作者认为,现行头孢洛林推荐剂量似乎足以覆盖合并肾脏清除增强的ICU患者中的肺炎链球菌,但不能覆盖MRSA。
- 作者认为,在受试方案中,负荷600 mg后以50 mg/h持续输注对MRSA感染可能更合适。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Ceftaroline could be suitable to treat early-onset ventilator-associated pneumonia (VAP) because of its antibacterial spectrum. However, augmented renal clearance (ARC) is frequent in ICU patients and may affect ceftaroline pharmacokinetics and efficacy. The objective of the study was to explore the impact of ARC on ceftaroline pharmacokinetics and evaluate whether the currently recommended dosing regimen (600 mg every 12 h) is appropriate to treat VAP in ICU patients. METHODS: A population pharmacokinetic model was developed using pharmacokinetic data from 18 patients with measured creatinine clearance (CLCR) ranging between 83 and 309 mL/min. Monte Carlo simulations were conducted to determine the PTA and the cumulative fraction of response (CFR) against Streptococcus pneumoniae and MRSA for five dosing regimens. Study registered at ClinicalTrials.gov (NCT03025841). RESULTS: Ceftaroline clearance increased non-linearly with CLCR, with lower concentrations and lower probability of reaching pharmacokinetic/pharmacodynamic targets when CLCR increases. For the currently recommended dosing regimen, the probability of having unbound ceftaroline concentrations above the MIC over the entire dose range is greater than 90% for MICs below 0.125 mg/L. Considering the distribution of MICs, this regimen would not be effective against MRSA infections (CFR between 21% and 67% depending on CLCR), but would be effective against S. pneumoniae infections (CFR >86%). CONCLUSIONS: The recommended dosing regimen of ceftaroline seems sufficient for covering S. pneumoniae in ICU patients with ARC, but not for MRSA. Among the dosing regimens tested it appears that a constant infusion (50 mg/h) after a loading dose of 600 mg could be more appropriate for MRSA infections.
引用
- Chauzy A, Gregoire N, Ferrandière M, et al. Population pharmacokinetic/pharmacodynamic study suggests continuous infusion of ceftaroline daily dose in ventilated critical care patients with early-onset pneumonia and augmented renal clearance. J Antimicrob Chemother. 2022. PMID: 36059138. doi:10.1093/jac/dkac299
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。